| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two splice variants are derived from the BCL-x gene, proapoptotic Bcl-x(s) and antiapoptotic Bcl-x(L), via alternative 5` splice site selection. In previous studies, our laboratory identified an RNA cis-element within exon 2 of Bcl-x pre-mRNA that is a ceramide responsive termed CRCE 1. In this study, mass spectrometric analysis identified the splicing factor SAP155, as an RNA trans-acting factor binding to the purine-rich CRCE 1. The interaction of SAP155 with CRCE 1 was confirmed by the addition of an anti-SAP155 antibody (Ab) to EMSA decreasing the mobility of a protein:CRCE 1 complex (SuperShift). Furthermore, the down-regulation of SAP155 in A549 cells by RNA interference (RNAi) technology resulted in the loss of a 155 kDa protein complexed with CRCE 1. Moreover, this down-regulation of SAP155 induced an increase in the Bcl-x(s) with a concomitant decrease in the Bcl-x(L) splice variants and immunoreactive protein levels, thereby decreasing the Bcl-x(L)/Bcl-x(s) ratio. Specific down-regulation of SAP155 also inhibited the ability of exogenous ceramide treatment to further induce the activation of the Bcl-x(s) 5` splice site. Additionally, the specific down-regulation of SAP155 sensitized cells to undergo apoptosis in response to daunorubicin in a manner similar to ceramide. Therefore, we have identified SAP155 as an RNA trans-acting factor that binds to CRCE 1, functions to regulate the alternative 5` splice site selection of Bcl-x pre-mRNA, and is required for ceramide to induce the activation of the Bcl-x(s) 5` splice site. Furthermore, we have demonstrated that activation of the Bcl-x(s) 5` splice site can increase the effectiveness of chemotherapeutic drug treatment, thus establishing a role for the alternative splicing mechanism of Bcl-x in chemotherapeutic sensitivity.--Massiello, A., Roesser, J. R., Chalfant, C. E. SAP155 binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5` splice site selection of Bcl-x pre-mRNA.
This article has been cited by other articles:
|
|
 |
|
  A. Zhou, A. C. Ou, A. Cho, E. J. Benz Jr., and S.-C. Huang Novel Splicing Factor RBM25 Modulates Bcl-x Pre-mRNA 5' Splice Site Selection Mol. Cell. Biol., October 1, 2008; 28(19): 5924 - 5936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Grosso, A. Q. Gomes, N. L. Barbosa-Morais, S. Caldeira, N. P. Thorne, G. Grech, M. von Lindern, and M. Carmo-Fonseca Tissue-specific splicing factor gene expression signatures Nucleic Acids Res., September 1, 2008; 36(15): 4823 - 4832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cloutier, J. Toutant, L. Shkreta, S. Goekjian, T. Revil, and B. Chabot Antagonistic Effects of the SRp30c Protein and Cryptic 5 ' Splice Sites on the Alternative Splicing of the Apoptotic Regulator Bcl-x J. Biol. Chem., August 1, 2008; 283(31): 21315 - 21324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hai, W. Cao, G. Liu, S.-P. Hong, S. A. Elela, R. Klinck, J. Chu, and J. Xie A G-tract element in apoptotic agents-induced alternative splicing Nucleic Acids Res., June 1, 2008; 36(10): 3320 - 3331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Revil, J. Toutant, L. Shkreta, D. Garneau, P. Cloutier, and B. Chabot Protein Kinase C-Dependent Control of Bcl-x Alternative Splicing Mol. Cell. Biol., December 15, 2007; 27(24): 8431 - 8441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Paronetto, T. Achsel, A. Massiello, C. E. Chalfant, and C. Sette The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x J. Cell Biol., March 26, 2007; 176(7): 929 - 939. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
